GlassScriptPhysician profile
Cynthia M Watson
NPI 1982795530
$2,073.35
in general payments reported to CMS, 2019-2025
19 companies · $166 in 2025
The $166 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $398 · 2021: $301 · 2022: $307 · 2023: $260 · 2024: $80.07 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $506.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $533.99 | 2019-2022 | |
| Ibsa Pharma INC. | $336.51 | 2019-2025 | Tirosint, Licart, Flector |
| Novo Nordisk INC | $301.28 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $145.07 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.96 | 2019-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $114.70 | 2019 | |
| Lilly USA, LLC | $109.97 | 2019-2025 | Mounjaro, Zepbound |
| Recordati_rare_diseases_inc. | $103.57 | 2025 | Isturisa |
| Harmony Biosciences LLC | $54.56 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $44.87 | 2021 | |
| Bausch Health US, LLC | $35.37 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.11 | 2022 | |
| Allergan, INC. | $25.49 | 2020 | |
| Avion Pharmaceuticals | $20.15 | 2022 | |
| Abbott Laboratories | $17.83 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $15.70 | 2023 | NP Thyroid 60 |
| Ascend Therapeutics US, LLC | $14.24 | 2020 | |
| Azurity Pharmaceuticals, INC. | $14.23 | 2023 | Adthyza |
| Pfizer INC. | $13.75 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.